Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Kidney Cancer | Primary research

A novel prognostic cancer-related lncRNA signature in papillary renal cell carcinoma

Authors: Binghai Chen, Di Dong, Qin Yao, Yuanzhang Zou, Wei Hu

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Papillary renal cell carcinoma (pRCC) ranks second in renal cell carcinoma and the prognosis of pRCC remains poor. Here, we aimed to screen and identify a novel prognostic cancer-related lncRNA signature in pRCC.

Methods

The RNA-seq profile and clinical feature of pRCC cases were downloaded from TCGA database. Significant cancer-related lncRNAs were obtained from the Immlnc database. Differentially expressed cancer-related lncRNAs (DECRLs) in pRCC were screened for further analysis. Cox regression report was implemented to identify prognostic cancer-related lncRNAs and establish a prognostic risk model, and ROC curve analysis was used to evaluate its precision. The correlation between RP11-63A11.1 and clinical characteristics was further analyzed. Finally, the expression level and role of RP11-63A11.1 were studied in vitro.

Results

A total of 367 DECRLs were finally screened and 26 prognostic cancer-related lncRNAs were identified. Among them, ten lncRNAs (RP11-573D15.8, LINC01317, RNF144A-AS1, TFAP2A-AS1, LINC00702, GAS6-AS1, RP11-400K9.4, LUCAT1, RP11-63A11.1, and RP11-156L14.1) were independently associated with prognosis of pRCC. These ten lncRNAs were incorporated into a prognostic risk model. In accordance with the median value of the riskscore, pRCC cases were separated into high and low risk groups. Survival analysis indicated that there was a significant difference on overall survival (OS) rate between the two groups. The area under curve (AUC) in different years indicated that the model was of high efficiency in prognosis prediction. RP11-63A11.1 was mainly expressed in renal tissues and it correlated with the tumor stage, T, M, N classifications, OS, PFS, and DSS of pRCC patients. Consistent with the expression in pRCC tissue samples, RP11-63A11.1 was also down-regulated in pRCC cells. More importantly, up-regulation of RP11-63A11.1 attenuated cell survival and induced apoptosis.

Conclusions

Ten cancer-related lncRNAs were incorporated into a powerful model for prognosis evaluation. RP11-63A11.1 functioned as a cancer suppressor in pRCC and it might be a potential therapeutic target for treating pRCC.
Appendix
Available only for authorised users
Literature
1.
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs—Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.PubMedCrossRef
2.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.PubMedCrossRef
3.
Akhtar M, Al-Bozom IA, Al Hussain T. Papillary renal cell carcinoma (PRCC): an update. Adv Anat Pathol. 2019;26(2):124–32.PubMedCrossRef
4.
Krawczyk KM, Nilsson H, Allaoui R, Lindgren D, Arvidsson M, Leandersson K, et al. Papillary renal cell carcinoma-derived chemerin, IL-8, and CXCL16 promote monocyte recruitment and differentiation into foam-cell macrophages. Lab Invest. 2017;97(11):1296–305.PubMedPubMedCentralCrossRef
5.
Zhang Y, Tang L. The application of lncRNAs in cancer treatment and diagnosis. Recent Pat Anti-Cancer Drug Discov. 2018;13(3):292–301.CrossRef
6.
7.
8.
Rao A, Rajkumar T, Mani S. Perspectives of long non-coding RNAs in cancer. Mol Biol Rep. 2017;44(2):203–18.PubMedCrossRef
9.
Denaro N, Merlano MC, Lo Nigro C. Long noncoding RNAs as regulators of cancer immunity. Mol Oncol. 2019;13(1):61–73.PubMedCrossRef
10.
Li J, Li Z, Leng K, Xu Y, Ji D, Huang L, et al. ZEB1-AS1: a crucial cancer-related long non-coding RNA. Cell Prolif. 2018;51(1):e12423.
11.
Thin KZ, Liu X, Feng X, Raveendran S, Tu JC. LncRNA-DANCR: a valuable cancer related long non-coding RNA for human cancers. Pathol Res Pract. 2018;214(6):801–5.PubMedCrossRef
12.
13.
Li J, Li Z, Zheng W, Li X, Wang Z, Cui Y, et al. PANDAR: a pivotal cancer-related long non-coding RNA in human cancers. Mol bioSyst. 2017;13(11):2195–201.PubMedCrossRef
14.
Zhang X, Li T, Wang J, Li J, Chen L, Liu C. Identification of cancer-related long non-coding RNAs using XGBoost with high accuracy. Front Genet. 2019;10:735.PubMedPubMedCentralCrossRef
15.
Wang J, Zhang X, Chen W, Li J, Liu C. CRlncRNA: a manually curated database of cancer-related long non-coding RNAs with experimental proof of functions on clinicopathological and molecular features. BMC Med Genom. 2018;11(Suppl 6):114.CrossRef
16.
Li Y, Jiang T, Zhou W, Li J, Li X, Wang Q, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11(1):1000.PubMedPubMedCentralCrossRef
17.
Lan H, Zeng J, Chen G, Huang H. Survival prediction of kidney renal papillary cell carcinoma by comprehensive LncRNA characterization. Oncotarget. 2017;8(67):110811–29.PubMedPubMedCentralCrossRef
18.
Yang F, Song Y, Ge L, Zhao G, Liu C, Ma L. Long non-coding RNAs as prognostic biomarkers in papillary renal cell carcinoma. Oncol Lett. 2019;18(4):3691–7.PubMedPubMedCentral
19.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef
20.
Wei C, Liang Q, Li X, Li H, Liu Y, Huang X, et al. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. J Cell Biochem. 2019;120(9):14916–27.PubMedCrossRef
21.
Wen Jiang Q, Guo C, Wang Yu, Zhu. A nomogram based on 9-lncRNAs signature for improving prognostic prediction of clear cell renal cell carcinoma. Cancer Cell Int. 2019;19:208.PubMedCrossRef
22.
Huang DW, Brad T, Sherman, Richard A, Lempicki. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.CrossRef
23.
Volders P-J, Anckaert J, Verheggen K, Nuytens J, Martens L, Mestdagh P, et al. LNCipedia 5: towards a reference set of human long non-coding RNAs. Nucleic Acids Res. 2019;47(D1):D135–9.PubMedCrossRef
24.
Zhen Cao X, Pan Y, Yang Y, Huang H-B, Shen. The lncLocator: a subcellular localization predictor for long non-coding RNAs based on a stacked ensemble classifier. Bioinformatics. 2018;34(13):2185–94.PubMedCrossRef
25.
Courthod G, Tucci M, Di Maio M, Scagliotti GV. Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015;96(1):100–12.PubMedCrossRef
26.
27.
Flippot R, Beinse G, Boilève A, Vibert J, Malouf GG. Long non-coding RNAs in genitourinary malignancies: a whole new world. Nat Rev Urol. 2019;16(8):484–504.PubMedCrossRef
28.
Liu Z, Zhang Y, Han X, Li C, Yang X, Gao J, et al. Identifying cancer-related lncRNAs based on a convolutional neural network. Front Cell Dev Biol. 2020;8:637.PubMedPubMedCentralCrossRef
29.
Yu Y, Chen X, Cang S. Cancer-related long noncoding RNAs show aberrant expression profiles and competing endogenous RNA potential in esophageal adenocarcinoma. Oncol Lett. 2019;18(5):4798–808.PubMedPubMedCentral
30.
Mitobe Y, Takayama KI, Horie-Inoue K, Inoue S. Prostate cancer-associated lncRNAs. Cancer Lett. 2018;418:159–66.PubMedCrossRef
31.
Wang Z, Song Q, Yang Z, Chen J, Shang J, Ju W. Construction of immune-related risk signature for renal papillary cell carcinoma. Cancer Med. 2019;8(1):289–304.PubMedCrossRef
32.
Gao Z, Zhang D, Duan Y, Yan L, Fan Y, Fang Z, et al. A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma. PLoS ONE. 2019;14(3):e0211491.PubMedPubMedCentralCrossRef
33.
Zhang C, Zheng Y, Li X, Hu X, Qi F, Luo J. Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma. Ann Transl Med. 2019;7(18):427.PubMedPubMedCentralCrossRef
34.
Liu Y, Gou X, Wei Z, Yu H, Zhou X, Li X. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma. Aging. 2020;12(15):15359–73.PubMedPubMedCentralCrossRef
35.
Huynh NP, Gloss CC, Lorentz J, Tang R, Brunger JM, McAlinden A, et al. Long non-coding RNA GRASLND enhances chondrogenesis via suppression of the interferon type II signaling pathway. eLife. 2020;9:e49558.PubMedPubMedCentralCrossRef
36.
Wang Y, Du L, Yang X, Li J, Li P, Zhao Y, et al. A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer. Aging. 2020;12(3):2857–79.PubMedPubMedCentralCrossRef
37.
Li T, Ren J, Ma J, Wu J, Zhang R, Yuan H, et al. LINC00702/miR-4652-3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/β-catenin pathway. Biomed Pharmacother = Biomedecine & pharmacotherapi. 2019;113:108718.CrossRef
38.
Yu W, Li D, Ding X, Sun Y, Liu Y, Cong J, et al. LINC00702 suppresses proliferation and invasion in non-small cell lung cancer through regulating miR-510/PTEN axis. Aging. 2019;11(5):1471–85.PubMedPubMedCentralCrossRef
39.
Wang L, Ye TY, Wu H, Chen SY, Weng JR, Xi XW. LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2. Eur Rev Med Pharmacol Sci. 2019;23(3 Suppl):201–8.PubMed
40.
Yu D, Wang XY, Jin ZL. Linc00702 inhibits cell growth and metastasis through regulating PTEN in colorectal cancer. Eur Rev Med Pharmacol Sci. 2020;24(7):3624–32.PubMed
41.
Wang W, Dong ML, Zhang W, Liu T. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2. Eur Rev Med Pharmacol Sci. 2019;23(12):5229–34.PubMed
42.
Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 2018;495(1):947–53.PubMedCrossRef
Metadata
Title
A novel prognostic cancer-related lncRNA signature in papillary renal cell carcinoma
Authors
Binghai Chen
Di Dong
Qin Yao
Yuanzhang Zou
Wei Hu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02247-6

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Review

New insights into M1/M2 macrophages: key modulators in cancer progression

Primary research

The immune‐related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation

Review

Triple-negative breast cancer: understanding Wnt signaling in drug resistance

Primary research

MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2

Primary research

CircMED13L_012 promotes lung adenocarcinoma progression by upregulation of MAPK8 mediated by miR-433-3p

Review

Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits